O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+30.47%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.45B
AUM Growth
+$5.45B
(+9.1%)
Cap. Flow
-$287M
Cap. Flow
% of AUM
-5.27%
Top 10 Holdings %
Top 10 Hldgs %
39.03%
Holding
130
New
20
Increased
22
Reduced
29
Closed
17
Top Buys
| 1 |
ArriVent BioPharma
AVBP
|
$54.1M |
| 2 |
Cytokinetics
CYTK
|
$47.9M |
| 3 |
Geron
GERN
|
$40.9M |
| 4 |
Q32 Bio
QTTB
|
$38.4M |
| 5 |
Esperion Therapeutics
ESPR
|
$36.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.23% | 2,718,735 | – | – |
|
2
Eli Lilly
LLY
$657B
| $281M | 5.14% | 360,800 -4,600 | -1% | -$3.58M |
|
3
Edgewise Therapeutics
EWTX
$1.51B
| $274M | 5.02% | 15,021,721 +454,545 | +3% | +$8.29M |
|
4
Boston Scientific
BSX
$156B
| $224M | 4.11% | 3,273,000 -33,800 | -1% | -$2.31M |
|
5
Intuitive Surgical
ISRG
$170B
| $197M | 3.6% | 493,100 -5,900 | -1% | -$2.35M |
|
6
Biogen
BIIB
$19.4B
| $194M | 3.56% | 900,900 +73,300 | +9% | +$15.8M |
|
7
Merck
MRK
$210B
| $174M | 3.18% | 1,316,000 +261,000 | +25% | +$34.4M |
|
8
Janux Therapeutics
JANX
$1.37B
| $161M | 2.95% | 4,275,553 +957,626 | +29% | +$36.1M |
|
9
Enliven Therapeutics
ELVN
$1.2B
| $158M | 2.9% | 8,998,338 | – | – |
|
10
Tenet Healthcare
THC
$16.3B
| $123M | 2.26% | 1,173,300 -51,100 | -4% | -$5.37M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $112M | 2.05% | 1,278,500 -292,910 | -19% | -$25.6M |
|
|
ALPN
12
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $106M | 1.95% | 2,680,496 +145,251 | +6% | +$5.76M |
|
13
Disc Medicine
IRON
$2.07B
| $106M | 1.94% | 1,702,237 | – | – |
|
14
Stryker
SYK
$150B
| $96.3M | 1.76% | 269,000 | – | – |
|
15
ARS Pharmaceuticals
SPRY
$1.15B
| $94.4M | 1.73% | 9,240,887 | – | – |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $90.3M | 1.65% | 697,500 | – | – |
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $87.3M | 1.6% | 2,013,033 -51,764 | -3% | -$2.24M |
|
18
Elevance Health
ELV
$71.8B
| $87.2M | 1.6% | 168,100 +26,600 | +19% | +$13.8M |
|
19
Xtant Medical Holdings
XTNT
$83.3M
| $85.5M | 1.57% | 73,114,592 | – | – |
|
20
Evolent Health
EVH
$1.12B
| $85.4M | 1.56% | 2,605,615 -140,917 | -5% | -$4.62M |
|
|
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
| $84M | 1.54% | 1,707,331 -1,512,028 | -47% | -$74.4M |
|
22
Keros Therapeutics
KROS
$618M
| $84M | 1.54% | 1,268,734 | – | – |
|
23
Natera
NTRA
$23.1B
| $82.3M | 1.51% | 899,431 -55,050 | -6% | -$5.03M |
|
24
Thermo Fisher Scientific
TMO
$186B
| $76.7M | 1.41% | 132,000 -11,800 | -8% | -$6.86M |
|
25
Apellis Pharmaceuticals
APLS
$3.48B
| $76.3M | 1.4% | 1,297,800 +375,600 | +41% | +$22.1M |
|